Establishment of noble therapy using allogeneic cultured dermal substitute combined with wound dressing containing epidermal growth factor

本研究的目的是建立一种新的治疗皮肤缺损的方法，使用同种异体培养皮肤替代物结合创面敷料含有表皮生长因子（EGF）。最后研制出一种性能优良的双层培养真皮替代物。上层是透明质酸（HA）和胶原蛋白（Col）海绵片与表皮生长因子（EGF）。下层是含有成纤维细胞的HA海绵片和Col凝胶。CDS很有前途，因为冷冻保存、解冻和冲洗过程不会造成细胞损伤的风险。CDS在无血清培养基中制备，然后置于伤口表面上。关键的问题是如何减少在无血清培养基中长时间孵育期间的细胞损伤。在无血清培养基中孵育几天后，可以使用EGF掺入的CDS。这段时间足以将CDS从生产设施运输到医院。 这种CDS有望成为一种实用的治疗方法。

This study aimed to establish a novel therapy for skin defect using allogeneic cultured skin substitute combined with wound dressing containing epidermal growth factor (EGF). Finally we developed an excellent two-layered cultured dermal substitute (CDS). The upper layer is a hyaluronic acid (HA) and collagen (Col) spongy sheet with epidermal growth factor (EGF). The lower layer is a HA spongy sheet and Col gel containing fibroblasts. The CDS is promising, because there is no risk of cellular damage caused by cryopreservation, thawing and rinsing processes. The CDS is prepared in serum-free medium, followed by placing on a wound surface. The critical issue is how to reduce the cellular damage during a prolonged period of incubation in serum-free medium. EGF-incorporating CDS can be used after a period of several days incubation in serum-free medium. This period is sufficient for transport of CDS from manufacturing facilities to hospitals. This CDS is promising for a practical therapy.